晚期头颈部鳞癌的内科治疗方案解读.pptVIP

- ERBITUX monotherapy led to improved efficacy compared with various other second-line therapies. - ERBITUX monotherapy was associated with a response rate of 13% compared with 3% for all patients in the retrospective study. This effect was even more pronounced when the results with ERBITUX monotherapy were compared with those for a sub-group of patients in the retrospective study who received various second-line chemotherapy regimens, none of whom responded to treatment. - The disease control rate achieved with ERBITUX monotherapy was also considerably higher than that seen in the retrospecti